LQDA Liquidia Corporation

Liquidia Corporation to Participate in Upcoming Investor Conferences

Liquidia Corporation to Participate in Upcoming Investor Conferences

MORRISVILLE, N.C., April 07, 2026 (GLOBE NEWSWIRE) -- Liquidia Corporation (NASDAQ: LQDA), a biopharmaceutical company driven by science and compassion to revolutionize care for patients with challenging respiratory and vascular diseases, today announced it will participate in upcoming investor conferences.

2026 Raymond James Biotech Innovation Symposium

Date: Tuesday, April 14, 2026

Location: Lotte New York Palace, New York, NY

Michael Kaseta, Chief Operating Officer and Chief Financial Officer, and Jason Adair, Chief Business Officer, will participate in one-on-one investor meetings.

25th Annual Needham Virtual Healthcare Conference

Date: Wednesday, April 15, 2026

Location: Virtual Event

In addition to hosting one-on-one meetings, Dr. Roger Jeffs, Chief Executive Officer, and Michael Kaseta will provide an update on the company's business during a fireside chat session beginning at 12:45 p.m. Eastern Time. Access to the webcast will be available on the “Investors” page of Liquidia’s website at . A replay and transcript of the webcast will be archived on the Company's website for at least 30 days.

About Liquidia Corporation

Liquidia Corporation is a biopharmaceutical company driven by science and compassion to revolutionize care for patients with challenging respiratory and vascular diseases through precise, innovative therapies and applications of its proprietary PRINT® Technology. PRINT enabled the creation of YUTREPIA® (treprostinil) inhalation powder for the treatment of pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD). The company is also developing L606, an investigational extended-release formulation of treprostinil administered twice-daily with a next-generation nebulizer, and currently markets generic Treprostinil Injection for the treatment of PAH. To learn more about Liquidia, please visit .



Contact Information

Investors:

Jason Adair

Chief Business Officer

919.328.4350





Media:



EN
07/04/2026

Underlying

LQDALiquidia Corporation

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Liquidia Corporation

 PRESS RELEASE
Free
LQDA Liquidia Corpor...

Liquidia Corporation to Participate in Upcoming Investor Conferences

Liquidia Corporation to Participate in Upcoming Investor Conferences MORRISVILLE, N.C., April 07, 2026 (GLOBE NEWSWIRE) -- Liquidia Corporation (NASDAQ: LQDA), a biopharmaceutical company driven by science and compassion to revolutionize care for patients with challenging respiratory and vascular diseases, today announced it will participate in upcoming investor conferences. 2026 Raymond James Biotech Innovation SymposiumDate: Tuesday, April 14, 2026Location: Lotte New York Palace, New York, NYMichael Kaseta, Chief Operating Officer and Chief Financial Officer, and Jason Adair, Chief Bus...

April 7, 2026 1 EN
 PRESS RELEASE
Free
LQDA Liquidia Corpor...

Liquidia Corporation Reports Fourth Quarter and Full Year 2025 Financi...

Liquidia Corporation Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update Achieved YUTREPIA® net product sales of $148.3 million for the full year 2025 with $90.1 million in the fourth quarterMore than 3,600 unique prescriptions received and 2,900 patients treated to date since launch in June 2025Ended 2025 with $190.7 million in cash and cash equivalents, an increase of $33.2 million from the third quarterRecorded second consecutive quarter of profitability MORRISVILLE, N.C., March 05, 2026 (GLOBE NEWSWIRE) -- Liquidia Corporation (NASDAQ: LQDA), a bi...

March 5, 2026 1 EN
 PRESS RELEASE
Free
LQDA Liquidia Corpor...

Liquidia Corporation to Report Full Year 2025 Financial Results on Mar...

Liquidia Corporation to Report Full Year 2025 Financial Results on March 5, 2026 MORRISVILLE, N.C., Feb. 26, 2026 (GLOBE NEWSWIRE) -- Liquidia Corporation (Nasdaq: LQDA), a biopharmaceutical company revolutionizing care for patients with challenging respiratory and vascular diseases, announced today that it will report its full year 2025 financial results on Thursday, March 5, 2026. The company will host a live webcast at 8:30 a.m. Eastern Time to discuss its financial results and provide a corporate update. The webcast will be available on Liquidia’s website at . A rebroadcast of the ev...

February 26, 2026 1 EN
 PRESS RELEASE
Free
LQDA Liquidia Corpor...

Liquidia to Present Clinical Data Across Its Portfolio at the Pulmonar...

Liquidia to Present Clinical Data Across Its Portfolio at the Pulmonary Vascular Research Institute 2026 Annual Congress MORRISVILLE, N.C., Jan. 27, 2026 (GLOBE NEWSWIRE) -- Liquidia Corporation (NASDAQ: LQDA), a biopharmaceutical company revolutionizing care for patients with challenging respiratory and vascular diseases, announced today the company will present three posters at the Pulmonary Vascular Research Institute (PVRI) 2026 Annual Congress to be held January 28 through February 1, 2026, in Dublin, Ireland. The presentations highlight clinical data in pulmonary arterial hypertensi...

January 27, 2026 1 EN
 PRESS RELEASE
Free
LQDA Liquidia Corpor...

Liquidia Corporation Announces Preliminary Full-Year 2025 YUTREPIA Net...

Liquidia Corporation Announces Preliminary Full-Year 2025 YUTREPIA Net Sales and Corporate Update Estimated YUTREPIA™ net product sales of approximately $90.1 million in the fourth quarter and $148.3 million for full-year 2025Received more than 2,800 unique patient prescriptions since launch in June 2025Generated more than $30 million of positive cash flow during the fourth quarter 2025 MORRISVILLE, N.C., Jan. 09, 2026 (GLOBE NEWSWIRE) -- Liquidia Corporation (NASDAQ: LQDA), a biopharmaceutical company driven by science and compassion to revolutionize care for patients with challenging ...

January 9, 2026 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch